NCT06217393已完成3 期
Randomized Multicentre Open-label Study to Investigate the Non-inferiority of Itopride Hydrochloride 150mg Once Daily Versus Itopride Hydrochloride 50 mg Thrice Daily in Subjects With Functional (Non-ulcer) Dyspepsia or Chronic Gastritis
Abbott26 个研究点 分布在 5 个国家目标入组 564 人开始时间: 2024年2月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 564
- 试验地点
- 26
- 主要终点
- Change in the Overall Severity of Functional Dyspepsia Between Baseline and Week 8, as Measured by the LDQ Severity Score
研究概览
简要总结
The study is conducted in patients with functional dyspepsia or chronic gastritis. The purpose of this study is to:
- assess whether the dose of Itopride Hydrochloride 150 mg extended release tablets, taken once daily has a similar effect on gastrointestinal symptoms caused by gastric dysmotility and delayed gastric emptying, like bloating sensation, early satiety, postprandial fullness, upper abdominal pain or discomfort, anorexia, heartburn, nausea and vomiting in functional (non-ulcer) dyspepsia or chronic gastritis, as Itopride Hydrochloride 50 mg film coated tablets administered thrice a day.
- investigate assessment of the treatment provided to each participant.
- monitor safety and tolerability of Itopride Hydrochloride 150 mg extended release tablets, taken once daily before one of the main meals (preferably same meal throughout the treatment) and Itopride Hydrochloride 50 mg film coated tablets thrice daily before meals.
详细描述
This is a muti-national study, in subjects with functional dyspepsia. The study will screen approximately 700 subjects and include 564 subjects (282 subjects in both arms Test and Active control arm) and the treatment will be given as follows.
- Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before any of the main meals (preferably same meal throughout the treatment) OR
- Active Control group - Itopride Hydrochloride 50 mg film coated tablets thrice daily before meals Total study participation will include screening for two weeks, treatment duration of eight weeks and follow-up for one week after the end of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult male and/or non-pregnant non-lactating female subjects aged above 18 years.
- •Subjects provided written informed consent and are willing to participate in the study.
- •Subjects with functional (non-ulcer) dyspepsia according to Rome IV criteria including postprandial distress syndrome (PDS) and with or without EPS (epigastric pain syndrome) with one or more of the following:
- •bothersome postprandial fullness,
- •bothersome early satiation
- •bothersome epigastric pain,
- •bothersome epigastric burning for at least 12 weeks in the preceding 6 months
- •No evidence of organic, systemic, metabolic or structural disease likely to explain symptoms - Subjects who have to undergone physical examination and lab tests (including white-cell and red-cell counts, measurement of fasting blood sugar and liver-function tests), abdominal ultrasonography, and upper GI endoscopy* in order to rule out structural cause for symptoms of FD.
- •*history of upper GI endoscopy within 6 months prior to enrolment or at screening.
- •Baseline severity of at least moderate symptoms on LDQ (total score ≥ 9) at screening.
- •H. pylori negative documented test report within 3 months prior to enrolment or during screening.
排除标准
- •Known hypersensitivity to Itopride or any component of the formulation and to any other related drug.
- •Subject with history or presence of clinically relevant evidence of cardiovascular, neurological, gastrointestinal/hepatic, renal, psychiatric, respiratory, urogenital, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/ connective tissue, musculoskeletal, metabolic/nutritional, drug hypersensitivity, allergy, endocrine, major surgery or other relevant disease as revealed by medical history requiring treatment which at investigator's discretion might interfere with the study.
- •Subjects who cannot be treated with Itopride in line with the prescribing information.
- •Subjects scheduled for surgery during the study.
- •Subjects with a history of difficulty in swallowing.
- •Subject requiring concomitant treatment with anticholinergic drugs, drugs with narrow therapeutic index, sustained release or enteric-coated formulations.
- •Subjects taking Acid release inhibitors (e.g. histamine-2-receptor [H2]- antagonists, proton pump inhibitors [PPI], or potassium-competitive acid blockers), antacids (e.g. aluminium- or magnesium hydroxide, sodium bicarbonate), gastric mucosa protectors (e.g. sucralfate, rebamipide).
- •Subject with history of unusual bleeding and family history for bleeding disorders.
- •Subjects with only reflux-related symptoms or who have predominantly reflux-related symptoms.
- •Subjects with esophagitis, Barrett's esophagus, erosions or peptic ulcer disease within one year prior to the study or Zollinger-Ellison Syndrome.
- •Dyspepsia that is exclusively relieved by defecation or associated with a change in stool frequency or stool form to exclude IBS.
- •Clinically significant ECG abnormalities.
- •Subjects treated with Itopride or any other gastroprokinetic within 4 weeks prior to screening.
- •Subjects who took non-steroidal anti-inflammatory drugs for more than 2 weeks prior to screening
- •Subjects with refractory FD1 (defined as FD presenting symptoms continuing for at least 6 months, unresponsive to at least two medical treatments such as PPIs, prokinetics, or H. pylori eradication) as per investigator's discretion
- •History of or known inflammatory bowel disease (IBD) or coeliac disease.
- •History of or known severe hepatic, renal, pancreatic, cardiac, metabolic, hematological or malignant disease or trimethylaminuria.
- •Subjects with changed smoking status within the last three months.
- •History of or known GI malignancy or ulcers associated to malignancy or any alarm features for GI malignancy, e.g. GI bleeding.
- •Subjects who do not meet the criteria stated in concomitant medication section.
- •Subjects with history of severe depression, anxiety or other psychological disorders.
- •Females with child-bearing potential must agree to use an acceptable method of contraception during the study.
- •Subjects in whom an increase in gastrointestinal motility could be harmful, e.g., (history of) gastrointestinal hemorrhage, mechanical obstruction or perforation.
- •Specific food intolerance which is relieved by diet modifications (e.g. lactose intolerance, celiac disease).
- •Subjects with confirmed IBS as per Rome IV criteria.
- •Current alcohol or drug abuse.
- •History of abdominal surgery except appendectomy, cholecystectomy or hysterectomy, tubal ligations, bladder slings or vasectomies.
- •Hepatic cirrhosis or abnormal liver laboratory findings (defined as >3xULN of ALT or AST).
- •Subjects under hemodialysis therapy or having advanced chronic kidney disease (defined as eGFR <60 mL/min).
- •History of or known congestive heart failure NYHA class III and IV, or any other uncontrolled chronic diseases, such as: uncontrolled hypertension (systolic/diastolic blood pressure ≥160/100 mmHg); uncontrolled diabetes (HbA1c >8%).
- •Subjects currently being known to be afflicted by serious infection(s), or any known severe illness(es) which are judged by the investigator could interfere with subjects' safety and/or study evaluation.
研究组 & 干预措施
Active Control group - Itopride Hydrochloride 50 mg film
Active Comparator
干预措施: Itopride Hydrochloride 50 mg film coated tablets (Drug)
Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals
Experimental
Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)
干预措施: Itopride Hydrochloride 150 mg extended release tablets (Drug)
结局指标
主要结局
Change in the Overall Severity of Functional Dyspepsia Between Baseline and Week 8, as Measured by the LDQ Severity Score
时间窗: 8 weeks
Change in the overall severity of functional dyspepsia between baseline and week 8, as measured by the Leeds Dyspepsia Questionnaire (LDQ) severity score consisting of 15 questions, where questions 1-8 are used to measure the severity, on a scale of 0 to 5 (0= absence, 1= very mild, 5=very severe). End Result: Maximum severity score is 40, symptom free=0, very mild =1-4, mild=5-8, moderate=9-15, severe is 16-40
To assess the comparable efficacy of Itopride Hydrochloride 150 mg extended release tablet (administered once daily) and Itopride Hydrochloride 50 mg film coated tablets (administered TID) after 8 weeks' treatment
时间窗: 8 weeks
Change in the overall severity of functional dyspepsia between baseline and week 8, as measured by the Leeds Dyspepsia Questionnaire (LDQ) severity score
次要结局
- Change in the Overall Severity of Functional Dyspepsia Between Baseline and Week 4, as Measured by the LDQ Severity Score(4 weeks)
- Disease Specific Quality of Life (Nepean Dyspepsia Index NDI) Assessed at Baseline and Week 8 in Terms of Change in % of Functional Ability.(8 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Sensation of Bloating) After 4 Weeks of Treatment.(4 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Sensation of Bloating) After 8 Weeks of Treatment.(8 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Early Satiety) After 4 Weeks of Treatment.(4 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Early Satiety) After 8 Weeks of Treatment.(8 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Postprandial Fullness) After 4 Weeks of Treatment.(4 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Postprandial Fullness) After 8 Weeks of Treatment.(8 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Upper Abdominal Pain or Discomfort) After 4 Weeks of Treatment.(4 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Upper Abdominal Pain or Discomfort) After 8 Weeks of Treatment.(8 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Anorexia (Loss of Apetite)) After 4 Weeks of Treatment.(4 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Anorexia (Loss of Apetite)) After 8 Weeks of Treatment.(8 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Heartburn) After 4 Weeks of Treatment.(4 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Heartburn) After 8 Weeks of Treatment.(8 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Nausea) After 4 Weeks of Treatment.(4 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Nausea) After 8 Weeks of Treatment.(8 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Vomiting) After 4 Weeks of Treatment.(4 weeks)
- Change From Baseline of NRS 11 Score for Symptoms (Vomiting) After 8 Weeks of Treatment.(8 weeks)
- To assess the comparable efficacy of Itopride Hydrochloride 150mg extended release tablet (administered once daily) and Itopride Hydrochloride 50 mg film coated tablets (administered TID) after 4 weeks treatment.(4 weeks)
- Assess the symptomatology (sensation of bloating, early satiety, abdominal pain or discomfort, epigastric pain, epigastric burning, anorexia, heartburn, nausea and vomiting) of the disease in both treatment arms after 4 and 8 weeks of treatment.(8 weeks)
- Change in the overall severity of functional dyspepsia between baseline and week 4, as measured by the Leeds Dyspepsia Questionnaire (LDQ) severity score (range 0-40), where 0 is symptom free and 40 is severe dyspepsia(8 weeks)
- To assess quality of life for the two treatment arms using Disease Specific Quality of Life (Short Form - Nepean Dyspepsia Index SF-NDI) at baseline and end of treatment(8 weeks)
研究者
研究点 (26)
Loading locations...
相似试验
撤回
不适用
Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl FumarateRelapsing Remitting Multiple SclerosisNCT04925778Banner Life Sciences LLC
已完成
不适用
Identification of Gluten Sensitivity in Irritable Bowel SyndromeNon-celiac Gluten SensitivityIrritable Bowel SyndromeNCT04017585University of Bari40
终止
2 期
Gastrografin for Treating Small Bowel Obstruction in ChildrenSmall Bowel ObstructionNCT03573921Lawson Health Research Institute2
已完成
2 期
Probiotic Supplementation Among Adults With Recurrent Gastrointestinal SymptomsGastrointestinal SymptomsBloatingGasIndigestionAbdominal PainDefecation IrregularityNCT02277431University of Maryland, Baltimore80
已完成
不适用
Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic FibrosisCystic FibrosisNCT03801993Chris Goss402